on Eckert & Ziegler Strahlen- Und Medizintechnik AG (ETR:EUZ)
Eckert & Ziegler SE: Strong Underlying Momentum and Growth Prospects
The latest research update from NuWays AG recommends a BUY rating for Eckert & Ziegler SE, setting a target price of €23 over the next 12 months. Despite a modest reported sales growth of 3% in 2026, underlying sales are projected to grow by 9%, with an expected 21% rise in adjusted EBIT. This growth is attributed to strong demand in the Medical and Isotope Products segments.
Medical segment momentum is fueled by high-margin isotope sales and increased demand for Ga-68 and Lu-177 isotopes. Meanwhile, the Isotope Products segment anticipates a recovery as delayed projects normalize and energy sector demand improves. Positive developments in isotopes Lu-177 and Ac-225 further enhance the company's radiopharma positioning.
The report highlights the potential impact of oil prices on isotope demand, suggesting incremental benefits if prices remain elevated. Overall, Eckert & Ziegler SE is positioned for growth with a robust balance sheet and attractive valuation.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Eckert & Ziegler Strahlen- Und Medizintechnik AG news